Fed Circuit hands win to Galderma in Teva suit

The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

US appeals court upholds decision on wrinkle treatment

29 June 2023 Board did not violate procedure regarding ‘preliminary guidance’ say Federal Circuit judges | Medytox’s substitute claims found to be ‘unpatentable’.

Generics

Galderma sues Lupin over Oracea generic

7 December 2021 Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.

Americas

Nestlé Skin Health has face injection infringement claims thrown out

17 December 2019 Nestlé Skin Health will not face claims that it misappropriated trade secrets related to a training platform for teaching medical professionals how to perform facial injections, a US court has ruled.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Fed Circuit hands win to Galderma in Teva suit

More on this story

Editor's picks

Editor's picks

More features